StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of NASDAQ:ADXS opened at $0.03 on Friday. Ayala Pharmaceuticals has a one year low of $0.00 and a one year high of $1.49. The business’s 50-day simple moving average is $0.04 and its 200 day simple moving average is $0.17. The company has a market cap of $1.15 million, a P/E ratio of 0.00 and a beta of 1.81.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.